about a potential deal between President Donald Trump and a major pharmaceutical company.
In an opinion piece in The New York Times, Sanders said the Trump administration was “on the brink of making a bad deal” that would give the French drugmaker Sanofi the exclusive license to patents for a Zika vaccine.
Sanofi has been working on a vaccine for Zika since February 2016 and has received $43 million in government funding to get the drug through development.
Sanders wants Sanofi to promise it won’t charge super high prices for its vaccines.
“American consumers should not be forced to pay the highest price in the world for a vaccine we paid to help develop,” Sanders wrote. He pointed to Xtandi, a cancer drug that he has criticized in the past, as an example of a drug that was developed in part with government funding that now has a high list price — $129,000.
“Under this insane system, Americans pay twice,” he wrote.
The Zika virus, which is mainly transmitted by mosquitoes, has been spreading around the world since 2015. Only about 20% of people with the virus ever show symptoms, which most commonly include fever, rash, joint pain, and red eyes. There is no approved vaccine available, even though the disease has been around since 1947.
Zika is most troubling because of its link to birth defects, including microcephaly — a condition in which a child is born with an abnormally small head — in infants whose mothers have had Zika. The virus has also been linked to a neurological condition called Guillain-Barré syndrome.
Why developing a vaccine for Zika is difficult
Sanofi’s vaccine is still a long way from getting approved in the US, and there’s no guarantee the vaccine would work.
There’s still a lot we don’t know about Zika, how it spreads, and where it might be a problem by the time a vaccine is developed. For example, all the areas hit since 2015 may not need the vaccine, or the disease could change into another strain that the vaccine doesn’t necessarily hit.
“We’re assuming substantial financial and opportunity risks because there is no clear path to commercialization at this time, as the epidemiology of this infectious disease is still a moving target,” a Sanofi spokeswoman said in a statement emailed to Business Insider.
Sanofi has developed vaccines for other infectious diseases in the past, most recently getting approval for a vaccine for dengue, another mosquito-borne infection that affects as many as400 million people a year. It took Sanofi 20 years to get a dengue vaccine, and it cost Sanofi $1.7 billion. The vaccine isn’t approved in the US, but in the Philippines, it costs roughly $23.
Whether a vaccine for Zika would be profitable remains to be seen. But Sanders has made his stance on the issue clear.
“We must not hand this gift to a French drug company without making it pledge not to overcharge American consumers,” Sanders wrote.
Previous Published: https://goo.gl/WQ07Qx